DOCSLIB.ORG

Nucleoside Tetra- and Pentaphosphates Prepared Using a Tetraphosphorylation Reagent Are Potent Inhibitors of Ribonuclease A

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nucleoside Tetra- and Pentaphosphates Prepared Using a Tetraphosphorylation Reagent Are Potent Inhibitors of Ribonuclease A Nucleoside Tetra- and Pentaphosphates Prepared Using a Tetraphosphorylation Reagent Are Potent Inhibitors of Ribonuclease A The MIT Faculty has made this article openly available. Please share how this access benefits you. Your story matters. Citation Shepard, Scott M. et al. "Nucleoside Tetra- and Pentaphosphates Prepared Using a Tetraphosphorylation Reagent Are Potent Inhibitors of Ribonuclease A." Journal of the American Chemical Society 141, 46 (October 2019): 18400–18404 © 2019 American Chemical Society As Published http://dx.doi.org/10.1021/jacs.9b09760 Publisher American Chemical Society (ACS) Version Author's final manuscript Citable link https://hdl.handle.net/1721.1/128544 Terms of Use Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use. HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author J Am Chem Manuscript Author Soc. Author Manuscript Author manuscript; available in PMC 2020 February 12. Published in final edited form as: J Am Chem Soc. 2019 November 20; 141(46): 18400–18404. doi:10.1021/jacs.9b09760. Nucleoside Tetra- and Pentaphosphates Prepared Using a Tetraphosphorylation Reagent Are Potent Inhibitors of Ribonuclease A Scott M. Shepard†, Ian W. Windsor†, Ronald T. Raines*, Christopher C. Cummins* Department of Chemistry, Massachusetts Institute of Technology, Cambridge Massachusetts 02139, United States Abstract Adenosine and uridine 5′-tetra- and 5′-pentaphosphates were synthesized from an activated tetrametaphosphate ([PPN]2[P4O11], [PPN]2[1], PPN = bis(triphenylphosphine)iminium) and subsequently tested for inhibition of the enzymatic activity of ribonuclease A (RNase A). Reagent [PPN]2[1] reacts with unprotected uridine and adenosine in the presence of a base under anhydrous conditions to give nucleoside tetrametaphosphates. Ring opening of these intermediates with tetrabutylammonium hydroxide ([TBA][OH]) yields adenosine and uridine tetraphosphates (p4A, p4U) in 92% and 85% yields, respectively, from the starting nucleoside. Treatment of ([PPN]2[1]) with AMP or UMP yields nucleoside-monophosphate tetrametaphosphates (cp4pA, cp4pU) having limited aqueous stability. Ring opening of these ultraphosphates with [TBA][OH] yields p5A and p5U in 58% and 70% yield from AMP and UMP, respectively. We characterized inorganic and nucleoside-conjugated linear and cyclic oligophosphates as competitive inhibitors of RNase A. Increasing the chain length in both linear and cyclic inorganic oligophosphates resulted in improved binding affinity. Increasing the length of oligophosphates on the 5′ position of adenosine beyond three had a deleterious effect on binding. Conversely, uridine nucleotides bearing 5′ oligophosphates saw progressive increases in binding with chain length. We solved X- ray cocrystal structures of the highest affinity binders from several classes. The terminal phosphate of p5A binds in the P1 enzymic subsite and forces the oligophosphate to adopt a convoluted conformation, while the oligophosphate of p5U binds in several extended conformations, targeting multiple cationic regions of the active-site cleft. Secretory ribonucleases (RNases) are a diverse family of enzymes that catalyze the cleavage of RNA to elicit biological functions ranging from cell signaling to innate immunity.1,2 *Corresponding Authors: [email protected]; [email protected]. †S.M.S. and I.W.W. contributed equally. Supporting Information The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/jacs.9b09760. Synthetic details, spectra, kinetic data, and crystallographic data collection and refinement statistics (PDF) Accession Codes Structure data for the new compounds are available from the Protein Database under the following PDB codes: RNase A·cP6i complex, 6pvu; RNase A·p5A complex, 6pvv; RNase A·cp4pA complex, 6pvw; RNase A·p5U complex, 6pvx. The authors declare the following competing financial interest(s): The tetraphosphorylation reagent is covered in patent US10017388B2. Shepard et al. Page 2 Fundamental knowledge generated by studying RNase A, which derives from the bovine Author ManuscriptAuthor Manuscript Author Manuscript Author Manuscript Author pancreas, has shaped the fields of enzymology and protein chemistry.3,4 Furthermore, mammalian RNases have been shown to have angiogenic5 and neurotoxic activities,6 and targeted inhibitors of these enzymes may have human therapeutic potential.7 RNase A binds its substrates in enzymic subsites that interact with phosphoryl groups and nucleobases (Figure 1).8,9 Atypical nucleotides are among the best small-molecule inhibitors of RNase A. Diadenosine oligophosphates (Table 1, entries 5–7) are micromolar to submicromolar inhibitors that exhibit increasing affinity with longer phosphate chain lengths.10 Additionally, the highest affinity small-molecule inhibitors of RNase A, pyrophosphate-linked dinucleotides (Table 1, entries 1–4), have enhanced inhibition activity upon further phosphorylation.11 These observations prompted us to ask: can a simple oligophosphate on its own or appended to a single nucleoside serve as an effective small-molecule inhibitor of RNase A? In addition to canonical nucleoside mono-, di-, and triphosphates, nucleosides bearing longer oligophosphate chains are potent signaling molecules in biology.14–18 These and other related morphologies, such as dinucleotide oligophosphates,19–21 have been implicated in a variety of biological processes and ailments including hypertension22 and bacterial accumulation of polyphosphate.23–26 Nonetheless, the synthesis of oligophosphorylated compounds typically increases in difficulty with longer phosphate chains. Recently, methods have been developed to efficiently couple a triphosphate chain in one operation from 3− 14,27–32 trimetaphosphate (P3O9 ). Here, we extend this methodology to the 4− tetraphosphorylation of biomolecules, utilizing tetrametaphosphate (P4O12 ) to synthesize nucleoside tetraphosphates (p4N) and nucleoside pentaphosphates (p5N). Previous syntheses 33 of p4N have suffered from extremely low yields, requiring nucleoside triphosphates as starting materials,34 or iterative syntheses to add each additional phosphoryl group.13,23 The state-of-the-art synthesis of p4N involves coupling of trimetaphosphate and nucleoside 14 monophosphates. Here, we describe the facile synthesis of p4N and p5N by coupling tetrametaphosphate with nucleosides and nucleoside monophosphates, respectively (Figure 2). Utilizing tetraphosphorylation reagent 1 permits unprotected nucleosides to be converted to the corresponding p4N efficiently in a single operation. This is in contrast to the method of Taylor, which requires nucleoside monophosphates as the substrate.14 While enzymatic 35–37 methods have been reported, the few reported chemical syntheses of p5N have been limited in scope and low yielding.23,33 The activated tetrametaphosphate, [PPN]2[1], is synthesized by protonation of tetrametaphosphate and subsequent dehydration.38 Treatment of adenosine or uridine with [PPN]2[1] under rigorously anhydrous conditions leads to selective phosphorylation of the 5′ position. No satisfactory purification could be found for the resulting nucleoside- substituted tetrametaphosphates (cp4N, Figure 3), but treatment with [TBA][OH] results in ring opening to the linear tetraphosphates. HPLC purification in triethylammonium acetate buffer of the resulting mixtures gives adenosine tetraphosphate (p4A, Table 1, entry 18, 93% yield) and uridine tetraphosphate (p4U, Table 1, entry 25, 85% yield) as pure triethylammonium salts. J Am Chem Soc. Author manuscript; available in PMC 2020 February 12. Shepard et al. Page 3 Nucleoside 5′-pentaphosphates were obtained similarly by treatment of [PPN]2[1] with the Author ManuscriptAuthor Manuscript Author Manuscript Author Manuscript Author anhydrous TBA salts of pA and pU. The intermediate nucleoside-monophosphate substituted tetrametaphosphates, cp4pN, could be isolated in reasonable purity and were found to be stable in aqueous solution for several hours at room temperature before hydrolyzing to a mixture of nucleoside monophosphate, tetrametaphosphate, and nucleoside pentaphosphate. Treatment of cp4pN with excess [TBA][OH] results in selective ring opening to p5N in 24 h. The products were again purified by HPLC in triethylammonium acetate buffer, providing p5A (Table 1, entry 19, 58% yield) and p5U (Table 1, entry 26, 70% yield) as triethylammonium salts (Figure 3). Reagent 1 is highly moisture sensitive and must be prepared, stored, and utilized in an anhydrous environment, ideally inside a glovebox. We therefore developed a second phosphorylation methodology for the syntheses of both p4N and p5N, activating 38 [PPN]2[P4O12H2] in situ with dicyclohexylcarbodiimide (DCC) to form reagent 1. These reagents are bench stable, and this methodology can be utilized conveniently with a Schlenk line, although it suffers from lower yields (SI Sections 2.2 and 2.5). We performed inhibition kinetics using a fluorogenic substrate as described previously39 to assess the binding of oligophosphates to RNase A. In addition to the synthesized molecules, p4N and p5N, we assessed inhibition kinetics for a variety of inorganic phosphates to evaluate our hypothesis that longer oligophosphate chains increase binding affinity. Complementing previous reports of weak RNase A inhibition by orthophosphate (Pi, Table 1, entry 8) and pyrophosphate (P2i,
Load more

Recommended publications
  • The Role and Mechanisms of Action of Micrornas in Cancer Drug Resistance Wengong Si1,2,3, Jiaying Shen4, Huilin Zheng1,5 and Weimin Fan1,6*
    Si et al. Clinical Epigenetics (2019) 11:25 https://doi.org/10.1186/s13148-018-0587-8 REVIEW Open Access The role and mechanisms of action of microRNAs in cancer drug resistance Wengong Si1,2,3, Jiaying Shen4, Huilin Zheng1,5 and Weimin Fan1,6* Abstract MicroRNAs (miRNAs) are small non-coding RNAs with a length of about 19–25 nt, which can regulate various target genes and are thus involved in the regulation of a variety of biological and pathological processes, including the formation and development of cancer. Drug resistance in cancer chemotherapy is one of the main obstacles to curing this malignant disease. Statistical data indicate that over 90% of the mortality of patients with cancer is related to drug resistance. Drug resistance of cancer chemotherapy can be caused by many mechanisms, such as decreased antitumor drug uptake, modified drug targets, altered cell cycle checkpoints, or increased DNA damage repair, among others. In recent years, many studies have shown that miRNAs are involved in the drug resistance of tumor cells by targeting drug-resistance-related genes or influencing genes related to cell proliferation, cell cycle, and apoptosis. A single miRNA often targets a number of genes, and its regulatory effect is tissue-specific. In this review, we emphasize the miRNAs that are involved in the regulation of drug resistance among different cancers and probe the mechanisms of the deregulated expression of miRNAs. The molecular targets of miRNAs and their underlying signaling pathways are also explored comprehensively. A holistic understanding of the functions of miRNAs in drug resistance will help us develop better strategies to regulate them efficiently and will finally pave the way toward better translation of miRNAs into clinics, developing them into a promising approach in cancer therapy.
    [Show full text]
  • 140503 IPF Signatures Supplement Withfigs Thorax
    Supplementary material for Heterogeneous gene expression signatures correspond to distinct lung pathologies and biomarkers of disease severity in idiopathic pulmonary fibrosis Daryle J. DePianto1*, Sanjay Chandriani1⌘*, Alexander R. Abbas1, Guiquan Jia1, Elsa N. N’Diaye1, Patrick Caplazi1, Steven E. Kauder1, Sabyasachi Biswas1, Satyajit K. Karnik1#, Connie Ha1, Zora Modrusan1, Michael A. Matthay2, Jasleen Kukreja3, Harold R. Collard2, Jackson G. Egen1, Paul J. Wolters2§, and Joseph R. Arron1§ 1Genentech Research and Early Development, South San Francisco, CA 2Department of Medicine, University of California, San Francisco, CA 3Department of Surgery, University of California, San Francisco, CA ⌘Current address: Novartis Institutes for Biomedical Research, Emeryville, CA. #Current address: Gilead Sciences, Foster City, CA. *DJD and SC contributed equally to this manuscript §PJW and JRA co-directed this project Address correspondence to Paul J. Wolters, MD University of California, San Francisco Department of Medicine Box 0111 San Francisco, CA 94143-0111 [email protected] or Joseph R. Arron, MD, PhD Genentech, Inc. MS 231C 1 DNA Way South San Francisco, CA 94080 [email protected] 1 METHODS Human lung tissue samples Tissues were obtained at UCSF from clinical samples from IPF patients at the time of biopsy or lung transplantation. All patients were seen at UCSF and the diagnosis of IPF was established through multidisciplinary review of clinical, radiological, and pathological data according to criteria established by the consensus classification of the American Thoracic Society (ATS) and European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and the Latin American Thoracic Association (ALAT) (ref. 5 in main text). Non-diseased normal lung tissues were procured from lungs not used by the Northern California Transplant Donor Network.
    [Show full text]
  • Mechanisms for the Regulation of Pro-Death
    MECHANISMS FOR THE REGULATION OF PRO-DEATH GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE NUCLEAR ACCUMULATION IN RETINAL MÜLLER CELLS UNDER HIGH GLUCOSE CONDITIONS By E. CHEPCHUMBA KOECH YEGO Submitted in partial fulfillment of the requirements For the degree of Doctor of Philosophy Dissertation Advisor: Susanne Mohr, PhD Department of Physiology and Biophysics CASE WESTERN RESERVE UNIVERSITY May, 2010 2 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the thesis/dissertation of ____E Chepchumba Koech Yego______________________ candidate for the _____Doctor of Philosophy (PhD)________degree *. (signed) _____Corey Smith _________ (chair of the committee) __________Cathleen Carlin__________ ______________ __________Joseph LaManna_______ ____________ __________Carole Liedtke _______________________ __________Andrea Romani_________________________ __________Michael Simonson _ _ ________ Susanne Mohr _________ (date) _____March 11th, 2010______________ *We also certify that written approval has been obtained for any proprietary material contained therein. 3 Dedication This dissertation is dedicated to my grandparents Mark Tireito *, Dinah Tireito *, Asbel Cheruiyot, Hannah Cheruiyot*, and John Korir. *Deceased 4 TABLE OF CONTENTS Dedication .......................................................................................... 3 List of Figures ..................................................................................... 8 List of Tables ...................................................................................
    [Show full text]
  • Supplemental Information For
    Supplemental Information for: Gene Expression Profiling of Pediatric Acute Myelogenous Leukemia Mary E. Ross, Rami Mahfouz, Mihaela Onciu, Hsi-Che Liu, Xiaodong Zhou, Guangchun Song, Sheila A. Shurtleff, Stanley Pounds, Cheng Cheng, Jing Ma, Raul C. Ribeiro, Jeffrey E. Rubnitz, Kevin Girtman, W. Kent Williams, Susana C. Raimondi, Der-Cherng Liang, Lee-Yung Shih, Ching-Hon Pui & James R. Downing Table of Contents Section I. Patient Datasets Table S1. Diagnostic AML characteristics Table S2. Cytogenetics Summary Table S3. Adult diagnostic AML characteristics Table S4. Additional T-ALL characteristics Section II. Methods Table S5. Summary of filtered probe sets Table S6. MLL-PTD primers Additional Statistical Methods Section III. Genetic Subtype Discriminating Genes Figure S1. Unsupervised Heirarchical clustering Figure S2. Heirarchical clustering with class discriminating genes Table S7. Top 100 probe sets selected by SAM for t(8;21)[AML1-ETO] Table S8. Top 100 probe sets selected by SAM for t(15;17) [PML-RARα] Table S9. Top 63 probe sets selected by SAM for inv(16) [CBFβ-MYH11] Table S10. Top 100 probe sets selected by SAM for MLL chimeric fusion genes Table S11. Top 100 probe sets selected by SAM for FAB-M7 Table S12. Top 100 probe sets selected by SAM for CBF leukemias (whole dataset) Section IV. MLL in combined ALL and AML dataset Table S13. Top 100 probe sets selected by SAM for MLL chimeric fusions irrespective of blast lineage (whole dataset) Table S14. Class discriminating genes for cases with an MLL chimeric fusion gene that show uniform high expression, irrespective of blast lineage Section V.
    [Show full text]
  • Zinc Transporter Znt5/Slc30a5 Is Required for the Mast Cell–Mediated Delayed-Type Allergic Reaction but Not the Immediate-Type Reaction
    ARTICLE Zinc transporter Znt5/Slc30a5 is required for the mast cell–mediated delayed-type allergic reaction but not the immediate-type reaction Keigo Nishida,1,2 Aiko Hasegawa,1,3 Susumu Nakae,4,5,6 Keisuke Oboki,4,5 Hirohisa Saito,4,5 Satoru Yamasaki,1 and Toshio Hirano1,3 1Laboratory for Cytokine Signaling, RIKEN Research Center for Allergy and Immunology, Yokohama, Kanagawa 230-0045, Japan 2Immune system, Cooperation Program, Graduate School of Frontier Biosciences, Osaka University, Osaka 565-0871, Japan 3Laboratory of Developmental Immunology and the Core Research for Evolutional Science and Technology Program (CREST) of the Japan Science and Technology Agency, Graduate School of Frontier Biosciences, Graduate School of Medicine, and WPI Immunology Frontier Research Center, Osaka University, Osaka 565-0817, Japan 4Department of Allergy and Immunology, National Research Institute for Child Health and Development, Tokyo 157-8535, Japan 5Atopy Research Center, Juntendo University, Tokyo 113-8421, Japan 6Frontier Research Initiative, Institute of Medical Science, University of Tokyo, Tokyo 108-8639, Japan Zinc (Zn) is an essential nutrient and its deficiency causes immunodeficiency. However, it remains unknown how Zn homeostasis is regulated in mast cells and if Zn transporters are involved in allergic reactions. We show that Znt5/Slc30a5 is required for contact hypersen- sitivity and mast cell–mediated delayed-type allergic response but not for immediate passive cutaneous anaphylaxis. In mast cells from Znt5/ mice, Fc receptor I (FcRI)– induced cytokine production was diminished, but degranulation was intact. Znt5 was in- volved in FcRI-induced translocation of protein kinase C (PKC) to the plasma membrane and the nuclear translocation of nuclear factor B.
    [Show full text]
  • A New Rnase Sheds Light on the Rnase/Angiogenin Subfamily from Zebrafish
    A new RNase sheds light on the RNase/angiogenin subfamily from zebrafish Pizzo Elio, Antonello Merlino, Mimmo Turano, Irene Russo Krauss, Francesca Coscia, Anna Zanfardino, Mario Varcamonti, Adriana Furia, Concetta Giancola, Lelio Mazzarella, et al. To cite this version: Pizzo Elio, Antonello Merlino, Mimmo Turano, Irene Russo Krauss, Francesca Coscia, et al.. A new RNase sheds light on the RNase/angiogenin subfamily from zebrafish. Biochemical Journal, Portland Press, 2010, 433 (2), pp.345-355. 10.1042/BJ20100892. hal-00549894 HAL Id: hal-00549894 https://hal.archives-ouvertes.fr/hal-00549894 Submitted on 23 Dec 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Biochemical Journal Immediate Publication. Published on 04 Nov 2010 as manuscript BJ20100892 TITLE: A new RNase sheds light on the RNase/angiogenin subfamily from zebrafish Authors: Elio PIZZO*, Antonello Merlino†,‡, Mimmo Turano*, Irene Russo Krauss†, Francesca Coscia†, Anna Zanfardino*, Mario Varcamonti*, Adriana Furia*, Concetta Giancola†, Lelio Mazzarella†, ‡, Filomena Sica†, ‡, Giuseppe
    [Show full text]
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease
    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
    [Show full text]
  • P2X and P2Y Receptors
    Tocris Scientific Review Series Tocri-lu-2945 P2X and P2Y Receptors Kenneth A. Jacobson Subtypes and Structures of P2 Receptor Molecular Recognition Section, Laboratory of Bioorganic Families Chemistry, National Institute of Diabetes and Digestive and The P2 receptors for extracellular nucleotides are widely Kidney Diseases, National Institutes of Health, Bethesda, distributed in the body and participate in regulation of nearly Maryland 20892, USA. E-mail: [email protected] every physiological process.1,2 Of particular interest are nucleotide Kenneth Jacobson serves as Chief of the Laboratory of Bioorganic receptors in the immune, inflammatory, cardiovascular, muscular, Chemistry and the Molecular Recognition Section at the National and central and peripheral nervous systems. The ubiquitous Institute of Diabetes and Digestive and Kidney Diseases, National signaling properties of extracellular nucleotides acting at two Institutes of Health in Bethesda, Maryland, USA. Dr. Jacobson is distinct families of P2 receptors – fast P2X ion channels and P2Y a medicinal chemist with interests in the structure and receptors (G-protein-coupled receptors) – are now well pharmacology of G-protein-coupled receptors, in particular recognized. These extracellular nucleotides are produced in receptors for adenosine and for purine and pyrimidine response to tissue stress and cell damage and in the processes nucleotides. of neurotransmitter release and channel formation. Their concentrations can vary dramatically depending on circumstances. Thus, the state of activation of these receptors can be highly dependent on the stress conditions or disease states affecting a given organ. The P2 receptors respond to various extracellular mono- and dinucleotides (Table 1). The P2X receptors are more structurally restrictive than P2Y receptors in agonist selectivity.
    [Show full text]
  • Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases
    International Journal of Molecular Sciences Review Advances in Applying Computer-Aided Drug Design for Neurodegenerative Diseases Mootaz M. Salman 1,2,*,† , Zaid Al-Obaidi 3,4,†, Philip Kitchen 5 , Andrea Loreto 1,6, Roslyn M. Bill 5 and Richard Wade-Martins 1,2,* 1 Department of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3QX, UK; [email protected] 2 Oxford Parkinson’s Disease Centre, University of Oxford, South Parks Road, Oxford OX1 3QX, UK 3 Department of Pharmaceutical Chemistry, College of Pharmacy, University of Alkafeel, Najaf 54001, Iraq; [email protected] 4 Department of Chemistry and Biochemistry, College of Medicine, University of Kerbala, Karbala 56001, Iraq 5 School of Biosciences, College of Health and Life Sciences, Aston University, Aston Triangle, Birmingham B4 7ET, UK; [email protected] (P.K.); [email protected] (R.M.B.) 6 John Van Geest Centre for Brain Repair, University of Cambridge, Cambridge CB2 0PY, UK * Correspondence: [email protected] (M.M.S.); [email protected] (R.W.-M.) † Equal contribution. Abstract: Neurodegenerative diseases (NDs) including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and Huntington’s disease are incurable and affect millions of people worldwide. The development of treatments for this unmet clinical need is a major global research challenge. Computer-aided drug design (CADD) methods minimize the huge number of ligands that could be screened in biological assays, reducing the cost, time, and effort required to develop Citation: Salman, M.M.; Al-Obaidi, new drugs.
    [Show full text]
  • Presence of Diadenosine 5',5"'-Pl,P4-Tetraphosphate (Ap4a) In
    Proc. Nati. Acad. Sci. USA Vol. 73, No. 11, pp. 3984-3988, November 1976 Biochemistry Presence of diadenosine 5',5"'-Pl,P4-tetraphosphate (Ap4A) in mammalian cells in levels varying widely with proliferative activity of the tissue: A possible positive "pleiotypic activator" (signal nucleotide/growth regulation/adenine nucleotides) ELIEZER RAPAPORT AND PAUL C. ZAMECNIK The John Collins Warren Laboratories of the Huntington Memorial Hospital of Harvard University at the Massachusetts General Hospital, Boston, Mass. 02114 Contributed by Paul C. Zamecnik, September 10, 1976 ABSTRACT An accurate assay of diadenosine 5',5"- tuting the well-known pyrophosphate exchange (Eq. 1). P',P4-tetraphosphate [A(5') pppp(5')AJ, which was shown to be formed in vitro in the backreaction of the amino acid activation pppA + aa, + Eaal :± aal-pA-Eaa1 + pp [1] step, has been developed in various cell lines in culture and in + pppA normal mouse liver or hepatoma in vivo. Use of radioactive aal-pA-Eaal labeling of acid-soluble nucleotides to high specific activity ~ 'A(5')pppp(5')A + aa, + Eaal [2] followed by chromatographic separation techniques yielded levels of Ap4A varying from 5 to 0.05 1M (from 30 pmol/mg of However, in in vitro amino acid activation systems ATP was rotein to 0.15 pmol), depending on the doubling time of the cell shown to participate in the backreaction as well (Eq. 2), yielding line or the proliferative state of the cells. The levels of Ap4A in Ap4A, which was identified as a byproduct of the first step in cells is inversely related to their doubling time, varying from protein synthesis in vitro and in vivo (Escherichia coli and rat 0.1 X 10-4 of the cellular ATP levels in slowly growing cells to liver slice) (11-15).
    [Show full text]
  • Antitumor Effect of TAT-Oxygen-Dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells
    [CANCER RESEARCH 62, 2013–2018, April 1, 2002] Antitumor Effect of TAT-Oxygen-dependent Degradation-Caspase-3 Fusion Protein Specifically Stabilized and Activated in Hypoxic Tumor Cells Hiroshi Harada, Masahiro Hiraoka, and Shinae Kizaka-Kondoh1 Pharmaceuticals Division, Pharmaceutical R&D Department, POLA Chemical Industries, Inc., Totsuka-ku, Yokohama 244-0812 [H. H.]; Department of Therapeutic Radiology and Oncology, Kyoto University Graduate School of Medicine, Shogoin, Sakyo-ku, Kyoto 606-8507 [M. H.]; and Department of Molecular Oncology, Kyoto University Graduate School of Medicine, Sakyo-ku, Kyoto 606-8501 [S. K-K.], Japan ABSTRACT The ODD domain of HIF-1␣ is located in its central region and consists of ϳ200 amino acid residues. The ODD domain controls the Human solid tumors contain hypoxic regions that have considerably degradation of HIF-1␣ by the ubiquitin-proteasome pathway, and the lower oxygen tension than normal tissues. These impart resistance to deletion of this entire region is required for DNA binding and trans- radiotherapy and anticancer chemotherapy, as well as predisposing to increased tumor metastases. To develop a potentially therapeutic protein activation in the absence of hypoxic signaling (15). Recently, the drug highly specific for solid tumors, we constructed fusion proteins product of von Hippel-Lindau tumor suppressor gene was reported to selectively stabilized in hypoxic tumor cells. A model fusion protein, mediate ubiquitination and proteasomal degradation of HIF-1␣ under oxygen-dependent degradation (ODD)-␤-galactosidase (␤-Gal), composed normoxic conditions by interaction with the core of the ODD domain of a part of the ODD domain of hypoxia-inducible factor-1␣ fused to of HIF-1␣ (16–18).
    [Show full text]
  • Angiogenin In: Bikfalvi A, Ed
    Angiogenin In: Bikfalvi A, ed. Encyclopaedic Reference of Vascular Biology & Pathology. Berlin Heidelberg: Springer-Verlag, 2000: 16-29. Angiogenin Josette Badet INSERM, U427, Développement Humain: Croissance et Différentiation Université René Descartes 4 avenue de l'Observatoire, 75006 Paris, France e-mail: [email protected] Synonym DIP, degranulation inhibiting protein; RNase 5, pancreatic-type ribonuclease 5. Definition Ribonuclease with angiogenic activity Introduction Angiogenin is a plasma protein [1] with angiogenic [2] and ribonucleolytic [3] activities. It is the first angiogenic molecule to be isolated and characterised from a human tumour. The strategy of purification used by Professor Vallee and his co- workers was based on the observation by Professor Folkman that tumour growth depends on neovascularization, and their project was inspired by the hypothesis that anti-angiogenesis might be used as a therapeutic approach [4]. Angiogenin was originally purified from 2000 litres of serum-free medium conditioned by HT-29 human adenocarcinoma cells (yield: 500 ng/L), on the basis of its ability to induce neovascularization [2]. Angiogenin elicits new blood vessel formation in the chick chorioallantoic membrane, where only femtomole amounts were needed to induce angiogenesis [2], and in the rabbit cornea [2] and meniscus [5]. Angiogenin is also present in normal human tissues and fluids such as plasma [1, 6] and amniotic fluid [7]. Angiogenin is secreted in culture by vascular endothelial cells, aortic smooth muscle cells (SMC), fibroblasts and tumour cells [2, 8]. Angiogenin is a ribonuclease-related molecule. This cationic single-chain protein has 35% amino acid sequence identity with human pancreatic ribonuclease (RNase), many of the remaining residues being conservatively replaced [9].
    [Show full text]